74.7

Satish Shanbhag

Florida Cancer Specialists & Research Institute

Satish Shanbhag's research has made significant contributions to various fields of hematology and oncology. Their work on ocular involvement in Tempi Syndrome highlights the importance of considering eye symptoms in patients with this rare condition. The development of hemostatic and antithrombotic stewardship programs has improved patient safety, and their study on ITP management demonstrates the effectiveness of these programs. In cancer immunotherapy, Shanbhag's research has established clinical practice guidelines for immune checkpoint inhibitor-related adverse events and provided insights into the use of pembrolizumab in mycosis fungoides and Sézary syndrome. Their studies also explore issues such as synthetic cannabinoid-associated coagulopathy, ibrutinib-associated hemophagocytic lymphohistiocytosis, and the use of emicizumab in refractory acquired hemophilia A. Overall, Shanbhag's research aims to improve patient outcomes by advancing our understanding of these complex conditions and developing effective treatment strategies.

Hemophagocytic LymphohistiocytosisTreatmentFamilial Hemophagocytic LymphohistiocytosisImmune-related Adverse EventsPost-Transplant Lymphoproliferative DiseaseHematopoietic Cell TransplantationCutaneous LymphomasHodgkin's LymphomaT Cell TherapyImmune Checkpoint BlockadeGraft-versus-Host DiseaseAnemia
Commercial signal 74.2
Scientific signal 77.3
Social signal 77.1
Papers 41
1 Patent-to-paper cites
1,916 Paper cites

scientifiq.ai is an experimental platform. The platform relies on open source data and it may contain errors. Its primary goal is to advance scientific research on innovation.